Breaking News

Del Mar, Guangxi Wuzhou Expand Cancer Drug Pact

Agreement to include global markets for DAG

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Del Mar Pharmaceuticals (BC) Ltd. has entered a strategic collaboration with Guangxi Wuzhou Pharmaceutical Co. for the development of VAL-083, (DAG for Injection) in China. DAG for Injection is approved by the Chinese SFDA as a cancer chemotherapy for the treatment of Chronic Myelogenous Leukemia (CML) and lung cancer. Guangxi is licensed by SFDA to manufacture and sell VAL-083 in China for these indications. DelMar is conducting clinical studies using Guangxi’s drug product in the U.S. a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters